Bone Therapeutics S.A.. (4/26/18). "Press Release: Bone Therapeutics Strengthens Board with the Appointment of Claudia D’Augusta as Non-Executive Director". Gosselies.

	Organisation	Bone Therapeutics S.A. (Euronext Brussels + Paris: BOTHE)
	Group	Bone Therapeutics (Group)
	Organisation 2	TiGenix N.V. (Euronext + Nasdaq: TIG)
	Product	cell therapy
	Product 2	ALLOB® allogeneic bone cell product
	Index term 2	TiGenix–Takeda: investment, 201801– aquisition public cash takeover offer €520m for remaining 95.8% for €1.78/share
	Person	D’Augusta, Claudia (VectivBio 202203 CFO formerly TiGenix 201204 CFO)
	Person 2	Stéphenne, Jean (GSK Biologicals 200512 President)

> Claudia D'Augusta brings significant financial and capital markets experience

BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that it has appointed Claudia D’Augusta, Ph.D., to its Board of Directors as a Non-Executive Director.

Claudia D'Augusta is a seasoned financial professional with more than 20 years’ experience in corporate finance, capital markets and M&A. She is currently Chief Financial Officer at TiGenix N.V. and is part of the management team at TiGenix, which Takeda has announced its intention to acquire for EUR 520 million. Prior to TiGenix, Claudia D'Augusta held various other senior financial positions across a number of international public and private companies.

Claudia D’Augusta replaces Wim Goemaere, formerly Chief Financial Officer, who will step down as a Non-Executive Director of the Company.

Claudia D'Augusta holds a degree in Economics and a Ph.D. in Business Administration from the University of Bocconi, Milan, Italy.

Welcoming Claudia D’Augusta to the Bone Therapeutics Board, Jean Stéphenne, Chairman, said: "We are delighted to welcome Claudia D’Augusta to the Board of Directors. I have had the privilege of working with Claudia at TiGenix where she proved an extremely able Chief Financial Officer. I am confident Claudia will provide further valuable financial guidance and support as we continue to progress the Company towards commercialization.”

“On behalf of the Board and leadership team of Bone Therapeutics, I would like to extend my thanks to Wim Goemaere, who was a capable and supportive member of our management team and Board through many pivotal moments in the Company’s development. We wish him all the best with his future endeavours.”

Claudia D’Augusta, commented: “I’m pleased to join to the Board of Bone Therapeutics at this exciting time in the Company’s development. I believe Bone Therapeutics products have the potential to revolutionize the field of orthopaedics and bone diseases and I am looking forward to contributing to the Company’s future success.”

For further information, please contact:

Bone Therapeutics SA
Thomas Lienard, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Tel: +32 (0) 71 12 10 00
investorrelations@bonetherapeutics.com

For Belgium and International Media Enquiries
Consilium Strategic Communications
Amber Fennell, Jessica Hodgson and Hendrik Thys
Tel: +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com

For French Media and Investor Enquiries
NewCap Investor Relations & Financial Communications
Pierre Laurent, Louis-Victor Delouvrier and Nicolas Merigeau
Tel: + 33 (0)1 44 71 94 94
bone@newcap.eu

For US Media and Investor Enquiries
Westwicke Partners
John Woolford
Tel: + 1 443 213 0506
john.woolford@westwicke.com

About Bone Therapeutics

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Bone Therapeutics’ technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.

The Company’s primary clinical focus is ALLOB®, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB®, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis of the hip.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Record changed: 2023-06-05